Early phase value scan for biotechnology innovation
The registration of a medicinal product by EMA or FDA used to be the main driving critical success factor for the future sales of a new medicinal product. The current additional important criteria for reimbursement decisions are cost-effectiveness and budgetary impact, which are taken into considera...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2017-05-01
|
| Series: | The EuroBiotech Journal |
| Online Access: | https://doi.org/10.24190/ISSN2564-615X/2017/02.08 |